Patent · US Active

Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

US10434100B2 · kind B2 · utility

5Cited by

12References

20Claims

0Family size

Assignee

Lixte Biotechnology, Inc. · US

Inventors

Alan F. List · Tampa, US
David A. Sallman · Tampa, US
John S. Kovach · Rochester, US

Key dates

Filing date	Aug 20, 2018
Grant date	Oct 8, 2019
Priority date	—
Expiry date	Aug 20, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.